Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Eledon Pharmaceuticals, Inc. (ELDN : NSDQ)

• Company Description    Eledon Pharmaceuticals Inc. is a clinical stage biotechnology company. It develop treatments for an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Eledon Pharmaceuticals Inc., formerly known as Novus Therapeutics Inc., is based in IRVINE, Calif. Number of Employees: 12

• Price / Volume Information    Yesterday's Closing Price: $3.20 Daily Weekly Monthly 20 Day Moving Average: 22,566 shares Shares Outstanding: 13.76 (millions) Market Capitalization: $44.02 (millions) Beta: 1.94 52 Week High: $10.20 52 Week Low: $2.27 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% 9.49% 12 Week -16.67% -6.34% Year To Date -27.44% -11.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 19900 MACARTHUR BOULEVARD SUITE 550 - IRVINE,CA 92612 USA ph: 949-238-8090 fax: - investors@eledon.com http://www.eledon.com

• General Corporate Information    Officers David-Alexandre C. Gros - Chief Executive Officer and Director Keith A. Katkin - Chairman Paul Little - Chief Financial Officer Jan Hillson - Director Gary A. Lyons - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28617K101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 13.76 Most Recent Split Date: 10.00 (0.06:1) Beta: 1.94 Market Capitalization: $44.02 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.72 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.59 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.28 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -21.05% vs. Previous Quarter: -16.95% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -21.42 12/31/21 - -19.80 09/30/21 - -17.47 ROA 03/31/22 - -20.69 12/31/21 - -19.07 09/30/21 - -16.85 Current Ratio 03/31/22 - 26.82 12/31/21 - 20.07 09/30/21 - 23.62 Quick Ratio 03/31/22 - 26.82 12/31/21 - 20.07 09/30/21 - 23.62 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 11.36 12/31/21 - 11.46 09/30/21 - 11.94 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©